156 related articles for article (PubMed ID: 34935548)
1. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.
Li Y; Zhu M; Zhang X; Cheng D; Ma X
Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215
[TBL] [Abstract][Full Text] [Related]
3. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
[TBL] [Abstract][Full Text] [Related]
4. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer.
Zhang J; Yu XL; Zheng GF; Zhao F
Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang Y; Wu J; Huang G; Xu S
Cancer Manag Res; 2018; 10():6897-6904. PubMed ID: 30588095
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis.
Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD
Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
8. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis.
Qi M; Xiong X
Medicine (Baltimore); 2018 Dec; 97(51):e13666. PubMed ID: 30572486
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
11. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y
Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788
[TBL] [Abstract][Full Text] [Related]
13. Does hypermethylation of CpG island in the promoter region of the E-cadherin gene increase the risk of lung cancer? A meta-analysis.
Sun Z; Liu G; Xu N
Thorac Cancer; 2019 Jan; 10(1):54-59. PubMed ID: 30390382
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
15. Association between promoter methylation of DAPK gene and HNSCC: A meta-analysis.
Cai F; Xiao X; Niu X; Zhong Y
PLoS One; 2017; 12(3):e0173194. PubMed ID: 28249042
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
[TBL] [Abstract][Full Text] [Related]
17. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.
Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C
PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis.
Wang H; Zhou LY; Guan ZB; Zeng WB; Zhou LL; Liu YN; Pan XY
PLoS One; 2019; 14(1):e0210943. PubMed ID: 30682070
[TBL] [Abstract][Full Text] [Related]
19. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Zhang Z; Yan S; Cui H; Chen H; Liu J
Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the relationship between RARβ gene promoter methylation and non-small cell lung cancer.
Hua F; Fang N; Li X; Zhu S; Zhang W; Gu J
PLoS One; 2014; 9(5):e96163. PubMed ID: 24796328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
